Developing and validating a nomogram for predicting endoscopic hemostasis failure in cirrhotic patients with esophageal variceal bleeding

建立并验证用于预测肝硬化食管静脉曲张出血患者内镜止血失败的列线图

阅读:1

Abstract

BACKGROUND AND AIMS: This study aimed to create and validate a model to predict the failure of endoscopic hemostasis in Chinese cirrhosis patients with acute esophagogastric variceal bleeding (EGVB), enabling early identification of high-risk individuals. METHODS: A retrospective study analyzed 296 cirrhotic patients with EGVB who received emergency endoscopic therapy from January 2020 to February 2025. Patients were divided into success (n = 273) and failure (n = 23, defined as bleeding recurrence within 5 days) groups. LASSO regression optimized variable selection, and multivariate logistic regression identified independent predictors to create a nomogram. Internal validation used Bootstrap resampling (500 iterations). Model performance was assessed using ROC curves, calibration plots, and decision curve analysis (DCA), and compared with CTP (Child-Turcotte-Pugh), MELD (Model for End-Stage Liver Disease), and Rockall scores. RESULTS: The cumulative incidence of endoscopic failure was observed to be 7.8%. Independent predictors identified included a shock index (SI) > 1.2 (OR = 5.447), the presence of a red color (RC) sign (OR = 10.005), active bleeding observed during endoscopy (OR = 5.962), and the CTP (OR = 1.584). The nomogram exhibited superior discriminatory power with an AUC of 0.890 (95% CI: 0.820-0.960), outperforming the CTP (AUC = 0.771, 95% CI: 0.656-0.886; P < 0.001), MELD (AUC = 0.733, 95% CI: 0.616-0.849; P < 0.001), and Rockall (AUC = 0.656, 95% CI: 0.545-0.768; P < 0.001). Calibration was satisfactory as indicated by the Hosmer-Lemeshow test (χ(2) = 10.021, P = 0.263). DCA demonstrated a clinical net benefit across a broad range of thresholds. CONCLUSION: A validated nomogram that integrates the SI, RC sign, active bleeding, and CTP provides an effective prediction of the risk of endoscopic hemostasis failure in patients with cirrhotic EGVB, thereby facilitating timely intervention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。